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concentration. AMD is associated with variation in many 
lipoprotein subclasses, including increased HDL and IDL 
particles and decreased Apo A-1, VLDL, and chylomicron 
particles.  These data suggest widespread systemic dis-
turbance in lipid metabolism in the pathogenesis of AMD, 
including possible alterations in lipoprotein carrier capac-
ity.—Cheung, C. M. G., A. Gan, Q. Fan, M. L. Chee, R. S. Apte, 
C. C. Khor, I. Yeo, R. Mathur, C–Y. Cheng, T. Y. Wong, and 
E. S. Tai. Plasma lipoprotein subfraction concentrations are 
associated with lipid metabolism and age-related macular 
degeneration. J. Lipid Res. 2017. 58: 1785–1796.
Supplementary key words  high density lipoprotein • genetics • choles-
terylester transfer protein
Age-related macular degeneration (AMD) is one of the 
major causes of blindness worldwide (1, 2). Despite exten-
sive research, the pathogenesis of AMD remains elusive 
and is likely multifactorial, involving genetic, lifestyle, and 
systemic factors (3–5). Current treatment in the form of 
anti-vascular endothelial growth factor therapy mainly 
addresses the specific angiogenic complications of neo-
vascular AMD (nAMD). However, the response to these 
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drugs varies among individuals, and some eyes are unre-
sponsive to this therapy (6–10). Additional pathways other 
than angiogenesis may also play significant roles in the patho-
genesis of AMD and provide potential alternative means of 
therapy.
In this regard, several pathways have been implicated in 
the pathogenesis of AMD, including chronic inflammation, 
atherosclerosis, and lipid dysregulation (3, 4, 11–16). A pos-
sible link between lipids and AMD has been suggested, and, 
recently, high-dose statins were reported to lead to resolu-
tion of signs of AMD and vision improvement (17, 18). 
However, the relationship between lipids and AMD has 
been inconsistently documented, with most studies only ex-
amining conventional measures of plasma lipids [i.e., total 
cholesterol, triglycerides (TGs), HDL-C and LDL-C] and 
AMD. Plasma lipids are carried on a heterogenous group of 
lipoproteins, variations in the size and density of which can 
alter lipid function. Importantly, within the retina, there is 
evidence that a sophisticated system of cholesterol uptake, 
intracellular trafficking, storage, and elimination utiliz-
ing lipoproteins as intermediates plays an important role 
in retinal physiology (19–21). Lipoproteins derived from 
plasma have also been implicated as the major upstream 
source of fatty acids within Bruchs’ membrane and provide 
an energy source to the retina (19, 22, 23), in addition to 
performing important functional roles in the transport of 
C, vitamin E, lutein, and zeaxanthin for use by photorecep-
tors (24, 25). Detailed analyses of lipoprotein profiles have 
provided important insights into the pathogenesis of other 
chronic diseases, including cardiovascular disease, insulin 
resistance, and diabetic retinopathy, in which endothelial 
dysfunction and atherosclerosis have been implicated 
(26–28). Thus, dysregulation in lipid metabolism, possibly 
affecting lipoproteins, but not necessarily captured by 
conventional plasma lipid measures, may also play a sig-
nificant role in the pathogenesis of AMD.
In further support of this hypothesis are recent studies 
that show variants in genes involved in lipid metabolism, 
including hepatic lipase (LIPC), cholesterylester transfer pro-
tein (CETP), and ATP-binding cassette transporter A1 
(ABCA1), confer increased risk of AMD (29–32). Animal 
studies have confirmed that the reverse cholesterol pathway 
regulated by ABC transporters may be critical in the develop-
ment of a choroidal neovascularization (15). The proteins 
encoded by most of these cholesterol-related genes have also 
been immunolocalized to the retina (21). We recently com-
pleted a genome-wide association study in East Asian AMD 
and have identified a missense mutation (D442G) in the 
CETP gene that is associated with elevated HDL-C and an 
increased risk of nAMD. CETP mediates the transfer of 
cholesteryl ester from HDL to LDL (33). CETP deficiency 
generates enlarged HDL particles containing an excess of 
cholesteryl esters, which are thought to be dysfunctional 
and incapable of reverse cholesterol transport (34, 35). 
How genetic variants at the CETP locus influence or 
modulate the relationship between plasma lipids, lipo-
proteins, and AMD is unknown.
To address these major gaps, we examined the associa-
tion between lipoprotein phenotype (size and distribution) 
and AMD. We also explored the possibility that the CETP 
D442G mutation may mediate or modulate these associa-
tions. Our hypothesis is that patients with AMD have ab-
normal lipid metabolism, which may give rise to abnormal 
lipoprotein profile characterized by an increase in large 
HDL particles, which are inefficient carriers of cholesterol.
METHODS
Study design and participants
We performed a case-control study utilizing serum from 193 
participants of Chinese ethnicity with nAMD enrolled in a pro-
spective clinical cohort study, the Asian AMD Phenotyping Study; 
and 184 subjects with early AMD and 289 age and gender-matched 
controls free of AMD enrolled in the Singapore Chinese Eye Study. 
Both studies were approved by the Singhealth Institutional Review 
Board and were conducted in accordance with the Declaration of 
Helsinki (protocol nos. R697/47/2009 and R498/47/2006). De-
tailed methodology of both studies has been published previously 
(36–42), and all participants provided written informed consent 
(additional information is available in supplemental data).
The Asian AMD Phenotyping Study prospectively recruited 
a consecutive series of treatment-naıve Asian patients with exu-
dative maculopathy secondary to nAMD from the retinal clinic of 
the Singapore National Eye Centre since March 1, 2010, and is 
still ongoing (32–37). To facilitate comparison of potential risk 
factors, the Asian AMD Phenotyping study adopted methods 
modeled after the Singapore Epidemiology of Eye Disease pro-
gram, which enrolled more than 10,000 participants by using 
standardized methodology and photographic grading of AMD 
and risk factor assessment. The Singapore Chinese Eye Study is 
part of the Singapore Epidemiology of Eye Disease program 
and is a population-based cohort study of major eye diseases in 
urban Chinese adults ranging from 40 to 80 years of age residing 
in Singapore (42). Subjects were selected from a computer- 
generated list provided by the Singapore Ministry of Home Af-
fairs, using an age-stratified (by 10 year age groups) random sam-
pling method. The study took place between 2009 and 2011. A 
total of 3,353 Chinese persons were eligible, and 72.8% partici-
pated in the study. Subjects with early AMD and age- and gender-
matched controls without AMD were selected from this cohort.
Clinical evaluation
nAMD cases. Each patient was examined at baseline according 
to a standardized protocol derived in part from the Singapore 
Chinese Eye Study (42, 43). The examination procedures in-
cluded measurements of height, weight, blood pressure, and 
pulse rate, followed by a comprehensive ocular examination (vi-
sual acuity, dilated fundus examination, color fundus photogra-
phy, fluorescein angiography, indocyanine green angiography, 
and spectral domain optical coherence tomography). nAMD was 
diagnosed clinically and confirmed by ocular imaging results, 
which were graded by retinal specialists.
Early AMD cases and non-AMD controls. All participants had an 
interview, systemic examination and laboratory investigations to 
determine socioeconomic, ocular, and systemic risk factors. We 
used a digital fundus camera to capture color photographs of 
each eye after pupil dilation. Photograph of at least one eye of 
sufficient quality for assessment of AMD status was available in 
3,312 participants (98.8%). The Centre for Vision Research, Uni-
versity of Sydney, performed AMD grading using a modification of 
the Wisconsin Age-Related Maculopathy Grading System (43), which 
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defines early AMD as either soft indistinct or reticular drusen or 
both soft, distinct drusen plus retinal pigment epithelium (RPE) 
abnormalities. Early AMD cases and age- and gender-matched sub-
jects free of any stage of AMD were selected as controls for this study 
(Fig. 1).
Medical and drug history. A detailed interviewer-administered 
questionnaire was used to collect information about medical 
history (including hypertension, diabetes, angina, myocardial in-
farction, and stroke), medication including lipid-altering drugs, 
and cigarette smoking (defined as current, past, and never) in 
participants of both studies. The questionnaire was administered 
in English or translated into Chinese (Mandarin) and back-trans-
lated into English.
Lipids and lipoproteins
In both cohorts, a nonfasting venous blood sample was collected 
at baseline. Lipid biochemistry was performed by standard auto-
mated methods at the Biochemistry Department at the Singapore 
General Hospital, which utilized a Beckman Coulter ExC800 
automated chemistry analyzer. Total cholesterol, HDL-choles-
terol, TGs, and LDL-cholesterol were analyzed based on ho-
mogenous enzymatic colorimetry assay using 500 l of serum. 
Serum and plasma were extracted and stored at 80°C prior to 
DNA extraction.
Lipoprotein subclass levels and mean particle sizes were deter-
mined for all participants by NMR spectroscopy at LipoScience 
Inc. (Raleigh, NC) as previously described (26, 28), by using 
stored serum. Each NMR measurement produces the concentra-
tions of three subclasses of VLDL, LDL, and HDL particles each. 
From the subclass levels, the weighted-mean VLDL, LDL, and 
HDL particle sizes (nanometers in diameter) and particle concen-
trations were calculated. Lipoprotein subclasses were grouped as 
large LDL (21.3–23.0 nm), intermediate LDL (19.8–21.2 nm), 
small LDL (18.3–19.7 nm), large HDL (8.8–13.0 nm), medium 
HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm).
CETP genotyping and measurement
CETP D442G (rs2303790) genotype was determined from the 
existing Illumina Human OmniExpress genotyping or by using 
Taqman allelic discrimination probes (Applied Biosystems). The 
genotyped SNP rs2303790 was within Hardy-Weinberg Equilib-
rium in health controls (P = 0.190).
CETP concentration was determined by using a commercially 
available human cholesteryl ester transfer protein ELISA Kit 
(CSB-E08567h, Cusabio), which offers a detection range of 
0.195–50 ng/ml. Serum samples (100 µl) were used for the assay 
following dilution and preparation instructions supplied by the 
vendor.
Statistical analyses
All baseline and lipoprotein profile characteristics (LPCs) of 
study participants were summarized and compared between the 
three groups of study participants, namely, nAMD cases, early 
AMD cases, and age- and gender-matched controls. ANOVA using 
an F-test was conducted to compare the means of continuous 
variables, whereas a chi-squared or Fisher’s exact test was used 
to compare the proportional distribution of categorical vari-
ables between the three groups. Pairwise comparisons of the 
mean of each LPC were also performed by using Tukey’s honest 
significant difference test for multiple comparisons. For assessing 
crudely the presence of a linear trend relating the mean of each 
LPC with increasing AMD severity (from no AMD to early AMD to 
nAMD), an F-test of the linear orthogonal polynomial contrast 
was conducted, treating AMD severity as an equally spaced ordinal 
variable in a regression model.
D442G mutation carrier status was dichotomized, with individ-
uals carrying at least one mutant allele classified as mutation car-
riers. The mean of each LPC between D442G mutation carriers 
and noncarriers was compared in nAMD cases and controls sepa-
rately with a linear regression of the LPC against mutation status, 
adjusting for potential confounders of the relationship—age, gen-
der, BMI, current smoking status, lipid-lowering medication, hy-
pertension, diabetes, myocardial infarction, and stroke history. 
Because the mutation was very rare in the general population 
(3%), the original sample of age- and gender-matched controls 
had to be enriched with additional carriers of the mutation, with 
the augmented sample used only in this part of the analysis.
Each LPC was hereafter standardized to its distribution within 
age- and gender-matched controls for ease of comparing their ef-
fect sizes. To examine whether there was an independent associa-
tion between each standardized LPC and the risk of nAMD or 
early AMD, as compared against the comparably aged normal co-
hort, a logistic regression model that adjusted for the abovemen-
tioned potential confounders was used for each outcome. A 
cumulative proportional odds model was also fitted to assess 
whether change in each LPC was more generally associated with 
the risk of presenting with a more severe stage of AMD, here re-
garding AMD status as a three-level ordinal outcome—the results 
were by and large consistent with the effect estimates obtained 
from the separate logistic regression models and not presented 
for brevity. Whether the effect of each LPC on nAMD risk was 
influenced by the D442G mutation was lastly investigated by 
adding D442G mutation status as a covariate to the logistic re-
gression models. Expanded models allowing for interaction be-
tween each LPC and D442G mutation status were also studied 
to assess whether the said effects differed between mutation carri-
ers and noncarriers. Where evidence of interaction was found, 
estimates of the effect of the LPC on nAMD risk were presented 
separately in carriers and noncarriers of the mutation.
All estimated effects derived from logistic regression models 
were presented as odds ratios (ORs) per SD increase in each LPC. 
Two-sided Wald tests and t-tests were used to test the coefficients 
of interest in logistic and linear regression models, respectively, 
with statistical significance concluded at P < 0.05. Ninety-five per-
centage confidence intervals were presented for all reported 
Fig. 1. Mean serum concentration of HDL particles in partici-
pants with no AMD, early AMD, and nAMD. Participants with 
nAMD had significantly higher concentration of HDL compared 
with participants with early AMD (37.2 vs. 34.7 µmol/l), and com-
pared with controls (37.2 vs. 35.3 µmol/l). The increase in HDL 
particles was mainly driven by an excess of medium-sized parti-
cles in participants with nAMD, which was significantly higher 
compared with participants with early AMD (10.4 vs. 9.1 µmol/l) 
and compared with controls (10.4 vs. 9.1 µmol/l). * P < 0.001; 
** P = 0.003; #P = 0.026; ##P = 0.009.
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effect estimates. The statistical packages Stata 12 and R (version 
3.2.1) were used for the analyses.
Patient involvement
No patients were involved in setting the research question or 
the outcome measures. Patients were not involved in developing 
plans for recruitment, design, or implementation of the study or 
the interpretation and presentation of results. The results of the 
research will not be disseminated to the individual patient.
RESULTS
Lipoprotein phenotypes in nAMD cases, early AMD cases, 
and controls
The baseline characteristics of participants are summa-
rized in Table 1. Apart from slightly younger age in the 
early AMD group, there were no statistically significant 
differences in gender, BMI, smoking status, or history of 
hypertension, diabetes, myocardial infarction, or stroke 
between the three groups of patients. The proportion of 
subjects on lipid medication was similar in all three groups. 
The D442G minor frequency allele was present in 15.0% of 
the late AMD group, 2.2% of the early AMD group, and 
2.8% of controls. As expected, the presence of the D442G 
polymorphism was associated with increased risk of late 
AMD [OR = 6.1 (95% CI 2.7–13.7), P < 0.001]. Conven-
tional lipid biochemistry showed similar levels of HDL-C, 
LDL-C, and TGs between the three groups.
Results of detailed lipoprotein profile are summarized 
in Tables 2 and 3. Although HDL-C, LDL-C, and TGs were 
similar between nAMD cases and controls, more detailed 
examination of the lipoprotein particle revealed signifi-
cant differences between controls and patients with early 
or late AMD. First, nAMD cases had lower plasma levels of 
apo A-I (Apo-A1). Among the TG-rich lipoproteins, nAMD 
cases had lower concentrations of VLDL and chylomicron 
particles. These differences were attributable to lower con-
centrations of medium VLDL and chylomicron particles. 
Small VLDL particle concentration did not differ between 
groups. These lower levels of VLDL and chylomicron lev-
els were associated with higher levels of IDL, but lower lev-
els of large LDL particles. In relation to HDL particles, 
nAMD cases had a higher HDL particle concentration, 
which was largely due to an excess of medium HDL parti-
cles. Many of these associations showed a dose-dependent 
association with early AMD cases and nAMD cases (Tables 4  
and 5 and Fig. 1). In a supplementary analysis that in-
cluded only subjects who were not taking any lipid-lower-
ing medications, the associations related to ApoA1, LDL, 
VLDL, and chylomicrons and IDL remained statistically 
significant, whereas the associations related to HDL re-
mained in the same direction, although not reaching sta-
tistical significance.
Influence of CETP D442G polymorphism on lipoprotein 
phenotype
After multivariable adjustment, we found that for each 
SD increase in HDL particles, a 26% increase in nAMD risk 
was observed (P = 0.039). The associations between HDL 
and increased risk of nAMD observed remained significant 
after adjustment for the presence of the D442G polymor-
phism at the CETP locus (analysis performed but not 
shown). To further evaluate the effect of CETP D442G 
polymorphism on lipoprotein phenotypes independent of 
AMD, we measured the lipoprotein profile in a further 113 
non-AMD subjects who were carriers of the D442G muta-
tion (total of 121 non-AMD subjects carrying the D442G 
mutation) and compared them with 276 non-AMD con-
trols without the mutation (Table 6). Among these non-
AMD controls, presence of the CETP D442G mutation was 
associated with significantly reduced level of CETP protein 
(432.9 vs. 569.2 ng/ml, P < 0.001) and elevated HDL-C lev-
els (1.5 vs. 1.3 mmol/l, P < 0.001), as expected. Compari-
son of lipoprotein particle concentrations showed that 
D442G mutation was associated with lower medium VLDL, 
higher small VLDL, and larger LDL particle size. There was 
no significant difference in any of the lipoprotein particle 
concentration in AMD cases according to D442G mutation 
status.
TABLE 1. Baseline characteristics of controls, early AMD cases, and late AMD cases
Baseline variable P aNo AMD (n = 289) Early AMD (n = 178) nAMD (n = 193)
Age (years), mean (SD) 67.4 (9.3) 65.2 (9.7) 67.5 (10.0) 0.036
Male, % 59.9 53.9 61.1 0.316
BMI (kg/m2), mean (SD) 23.7 (3.8) 23.4 (3.7) 24.0 (4.0) 0.344
Current smoker, % 13.1 10.1 18.3 0.091
Self-reported hypertension, % 43.9 49.4 53.3 0.153
Self-reported diabetes, % 14.9 13.5 12.5 0.776
Self-reported myocardial infarction, % 6.2 6.2 5.3 0.919
Self-reported stroke, % 3.1 1.7 2.0 0.670
On lipid medication, % 35.9 33.3 35.8 0.838
Carrier of CETP D442G variant, % 2.8 2.2 15.0 <0.001
Conventional lipid biochemistry
 HDL-C (mmol/l), mean (SD) 1.3 (0.4) 1.3 (0.4) 1.4 (0.3) 0.214
 LDL-C (mmol/l), mean (SD) 3.1 (0.9) 3.2 (0.8) 3.0 (1.0) 0.136
 TG (mmol/l), mean (SD) 1.8 (1.1) 1.8 (1.2) 1.8 (0.9) 0.819
a ANOVA using an F-test was performed to compare the mean of continuous variables, whereas a chi-squared or 
Fisher’s exact test was used to compare proportions for categorical variables. Fisher’s exact test was used when one 
or more cells had a sample size 5.
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We found a significant interaction between D442G 
mutation and HDL-particle concentration on the risk of 
AMD (Table 7). In noncarriers of the D442G allele, higher 
levels of both total HDL and medium HDL particle 
numbers were associated with increased risk of nAMD. In 
carriers of the D442G allele, although there was a trend 
toward higher concentration of these particles with lower 
nAMD risks, the results were not statistically significant.
DISCUSSION
There is a strong biological rationale and underlying hy-
pothesis that lipid dysregulation may be involved in the 
pathogenesis of AMD. First, genetic studies have reported 
variants in several C-related genes to confer increased risk 
of AMD (29–32). Second, there is biochemical evidence 
to suggest that intraretinal lipid transport is facilitated 
by proteins similar to those in systemic lipid metabolism 
(11–13). Third, patients with AMD have an increased risk 
of atherosclerosis and coronary artery disease (CAD), and, 
likewise, atherosclerosis and cardiovascular disease are ma-
jor risk factors for development of AMD (44–48). Fourth, 
studies in primates (49, 50) and rodents (15, 16) have dem-
onstrated that oxidized lipids may accumulate in the retina 
and promote angiogenesis directly or via impaired macro-
phage cholesterol efflux, although we acknowledge that 
the relevance of these animal models to human AMD is 
uncertain.
Despite the strong biological rationale, the relationship 
between lipid metabolism and AMD has been inconsistently 
documented in clinical studies, with most studies exam-
ining only the conventional plasma lipid measures of TC, 
TG, HDL-C, and LDL-C levels. In the current study, we hy-
pothesized that patients with AMD may have abnormal lipid 
metabolism that may be reflected as changes in the subtype 
of lipoprotein particles in the blood. We demonstrated that 
patients with nAMD and early AMD exhibit marked differ-
ences in many lipoprotein subclasses tested compared with 
controls, characterized by higher concentrations of HDL 
particles, particularly medium-sized particles, and IDL par-
ticles, and lower concentrations of Apo A-1, VLDL, and chy-
lomicron particles (Tables 2–5). These findings are in line 
with the hypothesis that tissue lipids may represent thera-
peutic targets for the treatment and prevention of AMD.
Comparing and contrasting our observations in AMD 
with the relationship between lipoprotein profile and CAD 
provides insights into mechanisms. Although AMD has pre-
viously been associated with CAD, the pattern of associa-
tions of lipoprotein with AMD demonstrated in this study is 
not similar to that for CAD. Specifically, high VLDL and 
LDL particle concentrations are usually associated with 
increased risk of CAD, whereas we found that nAMD 
was associated with lower VLDL particle concentration. 
Conversely, total and large HDL particle concentrations 
are consistently inversely associated with CAD risk (51), 
whereas in our AMD cases, the association was positive. On 
the other hand, raised IDL observed in nAMD patients may 
be a shared risk factor with CAD, because this is known to 
be atherogenic.
We recently reported on a genome-wide association 
study in East Asians and identified a strong association 
TABLE 2. Comparison of lipoprotein profiles in controls, early AMD cases and nAMD cases
Mean (SD)
Pa
Pairwise comparison of meansa
P for linear 
trendbNo AMD (n = 289) Early AMD (n = 178) nAMD (n = 193)
Early AMD  
versus no AMD
nAMD versus  
no AMD
nAMD versus  
early AMD
Total particle concentration by subclass
 ApoA1, mg/ld. 155.8 (26.7) 154.6 (23.6) 145.3 (45.5) 0.002 0.928 0.002 0.017 <0.001
 HDL, µmoll/l 35.3 (6.0) 34.8 (5.2) 37.2 (7.4) <0.001 0.618 0.003 <0.001 0.001
 LDL, nmol/l 1,320.8 (439.6) 1,222.4 (360.8) 1,236.5 (416.9) 0.019 0.034 0.070 0.942 0.029
 VLDL and chylomicron 
lipoprotein, nmol/l
73.2 (30.5) 67.4 (28.4) 60.6 (23.2) <0.001 0.083 <0.001 0.049 <0.001
Lipoprotein size distribution by subclass
 HDL, µmol/l
  Large 7.1 (3.8) 6.9 (3.6) 6.9 (3.5) 0.838 0.878 0.868 1.000 0.614
  Medium 9.1 (5.0) 9.2 (4.5) 10.4 (5.0) 0.008 0.951 0.008 0.046 0.003
  Small 19.1 (6.4) 18.6 (5.7) 19.9 (6.4) 0.131 0.648 0.383 0.114 0.187
 IDL, nmol/l
  IDL 110.7 (79.6) 114.7 (82.6) 155.6 (110.6) <0.001 0.891 <0.001 <0.001 <0.001
 LDL, nmol/l
  Large 581.2 (264.5) 554.0 (240.4) 448.3 (269.6) <0.001 0.515 <0.001 <0.001 <0.001
  Small 628.8 (427.7) 553.7 (343.1) 632.6 (375.5) 0.084 0.111 0.994 0.129 0.917
 VLDL and chylomicron, nmol/l
  Large 6.6 (6.3) 6.1 (5.9) 5.2 (3.8) 0.030 0.639 0.022 0.270 0.008
  Medium 30.8 (19.4) 25.4 (16.2) 17.5 (12.1) <0.001 0.002 <0.001 <0.001 <0.001
  Small 35.8 (17.9) 36.0 (17.3) 37.9 (16.5) 0.394 0.989 0.392 0.555 0.192
Mean particle sizes
 HDL particle size, nm 9.2 (0.5) 9.3 (0.5) 9.3 (0.5) 0.064 0.371 0.057 0.691 0.022
 LDL particle size, nm 20.9 (0.6) 21.0 (0.6) 20.8 (0.6) 0.056 0.292 0.480 0.044 0.248
 VLDL particle size, nm 49.8 (7.5) 49.8 (8.2) 50.5 (7.6) 0.529 0.999 0.542 0.640 0.292
a ANOVA using an F-test was performed to compare mean lipoprotein levels between the three stages of AMD, and Tukey’s honest significant 
difference test was used for multiple pairwise comparisons.
b Evidence of trend was assessed by conducting an F-test of the linear orthogonal polynomial contrast in a regression model of lipoprotein level 
against AMD stage as a three-level ordinal variable.  at W
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between the CETP D442G mutation with nAMD (per-allele 
OR = 1.70) (33). CETP mediates the transfer of cholesteryl 
ester from HDL to LDL. Together with hepatic lipase LIPC, 
these two genes are the key genetic determinants of lipo-
protein sizes (52, 53). The D442G mutation is specific to 
Asians, with minor allele frequency of 0.03 in East Asians 
and <0.01 in Europeans. The mutant 442G allele is known 
to impair CETP function, resulting in reduced CETP mass 
and activity (34, 35, 54). Each copy of the dysfunctional 
442G allele conferred, on average, a rise in HDL-C levels of 
0.174 mmol/l. We were therefore particularly interested to 
investigate the potential influence of HDL particles on 
AMD risk. Our results demonstrated that increase in HDL 
particle concentration, particularly medium-sized particles, 
was significantly associated with nAMD.
To understand this association, we need to understand 
the function of HDL described in previous studies. HDL 
play a unique role in supporting reverse C transport, which 
represents a major pathway through which excess C in pe-
ripheral tissues, such as endothelium, can be removed. 
These particles therefore protect against effects from ex-
cess C in the peripheral tissues (55–57). Accumulation of 
intracellular C may also result from aging of macrophages, 
with features including abnormal polarization, downregu-
lation of ABCA1, and impaired C efflux, which, in turn, 
can lead to increased inflammation and a proangiogenic 
state (15). HDL-C may also have additional antiinflamma-
tory, antioxidant, antiaggregatory, anticoagulant, and pro-
fibrinolytic activities. However, these protective properties 
of HDL may vary according to the structure and function 
of the lipoprotein particles on which they are carried. 
Thus, our finding that risk of AMD was not associated with 
HDL-C, but was associated with the number of particles 
(particularly of medium-sized HDL particles), is interest-
ing, but not altogether surprising. In addition, our finding 
of reduced concentration of Apo A-1 in patients with 
nAMD further supports that the structure and function of 
HDL particles may be altered in AMD. Apo-A1 is a major 
apolipoprotein in HDL and one that is thought to mediate 
many of the protective effects of HDL. This suggests that 
the number of HDL particles, while increased, may be de-
pleted of Apo-A1, adversely affecting their ability to facili-
tate cholesterol efflux. In support of this hypothesis, within 
the retina, Apo-A1 has been observed in the apical region 
of the RPE, in the interphotoreceptor matrix of rod photo-
receptors, choroid, and neuroretina in monkey retina. The 
apical location within the RPE suggests that Apo-A1 may be 
secreted by RPE into the interphotoreceptor matrix (21). 
One proposed mechanism in which RPE can remove oxi-
dized lipids arising in the photoreceptor outer segments 
may be through transfer of the lipids into their endoge-
nous Apo-A1- and ApoE-containing HDL-like particles, 
which are, in turn, transported by ABCA1 out of the RPE. 
However, these endogenous HDL-like particles remain to 
be identified.
Although we confirmed our a priori hypothesis that per-
turbation in HDL metabolism would be the main changes 
seen in AMD, we were somewhat surprised to find that 
VLDL and chylomicron lipoprotein concentration was 
markedly reduced in subjects with AMD. In the retina, 




Pairwise comparison of meansa
P-value for  
linear trendbNo AMD (n = 184) Early AMD (n = 121) nAMD (n = 95)
Early AMD  
versus no AMD
nAMD versus  
no AMD
nAMD versus  
early AMD
Total particle concentration by subclass
 ApoA1, mg/dl 154.4 (27.0) 153.3 (20.0) 137.1 (45.8) <0.001 0.953 <0.001 <0.001 <0.001
 HDL, µmol/l 34.8 (6.0) 33.9 (4.7) 35.6 (7.0) 0.098 0.422 0.468 0.081 0.240
 LDL, nmol/l 1,426.5 (457.7) 1,239.5 (377.5) 1,316.9 (449.9) <0.001 <0.001 0.113 0.387 0.046
 VLDL and chylomicron 
lipoprotein, nmol/l
74.2 (31.0) 66.2 (29.4) 60.2 (23.9) <0.001 0.049 <0.001 0.284 <0.001
Lipoprotein size distribution by subclass
 HDL, µmol/l
  Large 7.0 (3.9) 7.0 (3.3) 6.9 (3.5) 0.971 0.999 0.969 0.981 0.812
  Medium 9.0 (5.2) 9.2 (4.6) 10.1 (5.7) 0.210 0.956 0.195 0.370 0.084
  Small 18.8 (6.6) 17.7 (5.4) 18.6 (5.7) 0.333 0.324 0.984 0.634 0.865
 IDL, nmol/l
  IDL 120.6 (81.2) 120.7 (89.2) 165.3 (111.0) <0.001 1.000 <0.001 0.001 <0.001
 LDL, nmol/l
  Large 637.7 (286.7) 574.0 (252.4) 495.2 (281.9) <0.001 0.121 <0.001 0.095 <0.001
  Small 668.2 (473.4) 543.8 (347.3) 656.4 (406.1) 0.034 0.034 0.973 0.129 0.824
 VLDL and chylomicron, nmol/l
  Large 6.8 (6.7) 6.1 (6.0) 5.2 (3.8) 0.078 0.514 0.065 0.499 0.025
  Medium 31.0 (20.0) 24.9 (16.4) 17.3 (11.4) <0.001 0.008 <0.001 0.004 <0.001
  Small 36.4 (18.3) 35.2 (18.7) 37.7 (17.8) 0.610 0.846 0.836 0.581 0.569
Mean particle sizes
 HDL particle size, nm 9.2 (0.5) 9.3 (0.5) 9.4 (0.5) 0.031 0.134 0.045 0.840 0.017
 LDL particle size, nm 20.9 (0.6) 21.0 (0.6) 20.9 (0.6) 0.169 0.216 0.977 0.241 0.837
 VLDL particle size, nm 49.4 (7.8) 49.8 (8.3) 50.3 (7.8) 0.647 0.907 0.622 0.877 0.354
a ANOVA using an F-test was performed to compare mean lipoprotein levels between the three stages of AMD, and Tukey’s honest significant 
difference test was used for multiple pairwise comparisons.
b Evidence of trend was assessed by conducting an F-test of the linear orthogonal polynomial contrast in a regression model of lipoprotein level 
against AMD stage as a three-level ordinal variable.
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studies have demonstrated that LDL is the major carrier 
of cholesterol from the systemic circulation into RPE and 
neurosensory retina (58–60). Although the function of 
these lipids within the retina remain to be elucidated, 
recent findings using VLDL receptor (VLDLR) KO mice 
suggest that lipid -oxidation is an important energy 
source for the retina. Fuel shortage resulting from reduced 
uptake of TG-derived fatty acid and glucose, in turn, leads to 
pathological angiogenesis in the retina through stabiliza-
tion of hypoxia-induced factor 1a and secretion of vascular 
endothelial growth factor A by photoreceptors (58–60). 
The relevance of the VLDLR to the pathogenesis of AMD 
is further supported by genetic association studies (61). 
The finding of markedly reduced VLDL particle concen-
tration from the current study further supports the hy-
pothesis that eyes with AMD require fatty acids from VLDL. 
It is our hypothesis that the reduced availability of VLDL 
results in reduced fatty acid uptake by the retinal cells, which 
may, in turn, result in a proangiogenic state. The mecha-
nism leading to the low VLDL in AMD patients is unclear, 
but may include reduced production from the liver, in-
creased catabolism by LPL, and increased uptake by tissues 
other than the eye. However, associations between variants 
at the LPL locus and increased susceptibility to AMD have 
so far been inconsistently described (29, 62, 63).
We explored the possibility that the presence of the 
D442G mutation at the CETP locus may explain the asso-
ciation between lipoprotein particle concentrations and 
AMD (Table 6). In controls, the presence of the 442G al-
lele was associated with lower CETP activity and higher 
HDL-C, a finding that is consistent with previous studies 
(54, 64, 65). However, inclusion of the D442G mutation in 
the model did not significantly alter the association between 
HDL particle concentrations and increased risk of nAMD. 
As such, factors other than this mutation in CETP must play 
an important role in the pathogenesis of dyslipidemia as-
sociated with AMD. First, other mutations at the CETP lo-
cus may be important. Six polymorphisms in CETP have 
previously been described (26). Of specific relevance, the 
presence of the V405 allele of rs5882 has a similar, but 
smaller, effect to D442G mutation and is associated with 
higher HDL-C and reduced CETP activity. This polymor-
phism has been reported to be associated with polypoidal 
choroidal vasculopathy, a subtype of AMD common in 
Asians (62). Second, the effect of CETP mutations on AMD 
risk may not be mediated through HDL particles in the 
systemic circulation, but by a local effect in the retina. 
Indeed, CETP has been localized to the outer plexiform 
layer and the photoreceptor outer segments and interpho-
toreceptor matrix in monkey retina (21), suggesting that 
the retina has the ability to mature HDL particles locally 
and to transfer cholesterylester between lipoproteins. 
Therefore, dysfunction in CETP could lead to localized 
impairment of HDL maturation within the retina, re-
sulting in impaired lipid transfer between the RPE and 
photoreceptors.
TABLE 4. Relationship between the nAMD and early AMD with lipoprotein profiles
Early AMD versus controls nAMD versus controls
ORa (95% CI) P b ORa (95% CI) P b
Conventional lipid biochemistry
 HDL-C, mmol/l 1.05 (0.84–1.31) 0.664 1.33 (1.03–1.71) 0.027
 LDL-C, mmol/l 1.07 (0.86–1.35) 0.536 0.87 (0.69–1.11) 0.265
 TG, mmol/l 0.95 (0.77–1.18) 0.639 1.03 (0.78–1.35) 0.849
Total particle concentration by subclass
 ApoA1, mg/dl 0.86 (0.68–1.04) 0.105 0.68 (0.57–0.82) <0.001
 HDL particles (total,) µmol/l 0.79 (0.63–1.00) 0.053 1.26 (1.01–1.57) 0.039
 LDL particles (total), nmol/l 0.71 (0.55–0.90) 0.005 0.80 (0.63–1.02) 0.076
 VLDL and chylomicron particles (total), nmol/l 0.84 (0.68–1.04) 0.105 0.54 (0.41–0.71) <0.001
Lipoprotein size distribution by subclass
 HDL 
  Large 0.88 (0.70–1.11) 0.287 0.92 (0.71–1.18) 0.495
  Medium 0.98 (0.80–1.21) 0.877 1.24 (1.01–1.52) 0.039
  Small 0.90 (0.72–1.11) 0.321 1.07 (0.86–1.34) 0.523
 IDL 
  IDL particles 1.06 (0.86–1.29) 0.595 1.68 (1.38–2.04) <0.001
 LDL 
  Large 0.84 (0.68–1.04) 0.116 0.57 (0.44–0.72) <0.001
  Small 0.78 (0.62–0.99) 0.041 0.98 (0.78–1.23) 0.865
 VLDL and chylomicron
  Large 0.90 (0.72–1.12) 0.351 0.63 (0.47–0.86) 0.003
  Medium 0.74 (0.59–0.93) 0.009 0.30 (0.21–0.43) <0.001
  Small 1.03 (0.84–1.27) 0.754 1.10 (0.89–1.37) 0.356
Mean particle sizes
 HDL particle size 1.11 (0.89–1.38) 0.355 1.36 (1.08–1.71) 0.010
 LDL particle size 1.11 (0.90–1.37) 0.341 0.93 (0.74–1.17) 0.559
 VLDL particle size 0.99 (0.81–1.21) 0.904 1.04 (0.84–1.30) 0.713
a The OR relating a one SD increase in lipoprotein to early/late stage AMD was estimated from separate multiple 
logistic regression models adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering 
medication, self-reported hypertension, diabetes, myocardial infarction, and stroke.
bP-values were derived from Wald tests of the corresponding logistic regression coefficient relating each 
lipoprotein to early/late-stage AMD.
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There are limitations in the current study. Changes dem-
onstrated in plasma may not reflect the exact changes 
within the chorioretina. Future studies should aim to incor-
porate evaluation of cholesterol metabolism within the 
retina. In particular, further experiments based on human 
tissues will be needed to ascertain the translatability of 
studies in rodents and primates. Although we demon-
strated marked changes in all the subclasses of lipoproteins 
tested, we were not able to evaluate the relative influence 
of different pathways. Knowledge of which pathways are the 
most important will be essential in guiding future therapeu-
tic approaches. Because of the limited number of patients 
with nAMD in population studies, our case-control study 
compared subjects from a hospital-based cohort (the Asian 
AMD Phenotyping study) with those from a population-
based study (the Singapore Chinese Eye Study). Thus, de-
spite the carefully designed and standardized protocols 
between the two studies, we acknowledge that there remain 
inherent differences in cases and controls, and the possibil-
ity of selection bias. Approximately 35% of subjects in each 
AMD category was on lipid-lowering medication. However, 
it is unlikely that the associations reported are affected by 
lipid medication because we have included lipid-lowering 
medication as one of the variables in the multivariable 
models, and most of the associations remained significant, 
even in a subgroup analysis that included only subjects not 
taking lipid-lowering medications. Finally, blood samples 
were in nonfasting conditions. Ideally, we would have col-
lected the samples in the fasting state. However, the controls 
in this study were collected as part of a much larger study 
to examine the prevalence and risk factors of a number of 
different eye diseases in the Singapore population. Multi-
ple complex measurements related to eye disease were re-
quired, and, logistically, we were not able to study all the 
participants in the fasting state. For this reason, we col-
lected the blood samples from cases in the nonfasting state 
as well. We believe that lipid measurements in nonfasting 
samples would still be relevant. Most humans spend their 
day in the nonfasting state, and, therefore, the nonfasting 
state may actually be more physiologically relevant to 
health and disease than the fasting state. The use of fasting 
lipids for predicting the risk of future disease is largely his-
torical, and, for most purposes, measurement of lipids in 
the fasting state is considered preferable but not essential 
(66). In fact, the European Atherosclerosis Society and Eu-
ropean Federation of Clinical Chemistry and Laboratory 
Medicine recently issued a statement suggesting that fast-
ing is not essential for determination of a lipid profile in 
relation to predicting cardiovascular disease and making 
decisions on treatment. This is based on studies that have 
shown that nonfasting lipids are as (if not more) predictive 
of cardiovascular disease as fasting lipids (67, 68). This 
does not exclude the possibility that differences in the tim-
ing of blood sampling in relation to the last meal prior to 
blood sampling could bias the results. We feel that the pat-
tern of lipoproteins associated with AMD in this instance 
makes it less likely that our findings merely reflect bias 
due to the nonfasting samples. First, TG is one of the blood 
TABLE 5. Relationship between the nAMD and early AMD with lipoprotein profiles after excluding subjects taking lipid-lowering medications
Early AMD versus controls nAMD versus controls
ORa  (95% CI) P b ORa (95% CI) P b
Conventional lipid biochemistry
 HDL-C, mmol/l 1.12 (0.84–1.50) 0.431 1.54 (1.11–2.14) 0.010
 LDL-C, mmol/l 0.89 (0.67–1.16) 0.395 0.85 (0.65–1.12) 0.252
 TG, mmol/l 0.96 (0.75–1.24) 0.768 0.97 (0.68–1.38) 0.847
Total particle concentration by subclass
 ApoA1, mg/dl 0.918 (0.67–1.23) 0.536 0.64 (0.51–0.81) <0.001
 HDL particles (total,) µmol/l 0.81 (0.61–1.09) 0.166 1.19 (0.90–1.59) 0.227
 LDL particles (total), nmol/l 0.67 (0.42–0.78) <0.001 0.73 (0.55–0.99) 0.040
 VLDL and chylomicron particles (total), nmol/l 0.73 (0.56–0.96) 0.027 0.51 (0.36–0.72) <0.001
Lipoprotein size distribution by subclass
 HDL 
  Large 0.97 (0.72–1.31) 0.848 1.10 (0.80–1.52) 0.554
  Medium 1.03 (0.80–1.32) 0.845 1.25 (0.98–1.60) 0.073
  Small 0.83 (0.63–1.10) 0.193 0.89 (0.66–1.194) 0.435
 IDL 
  IDL particles 1.03 (0.81–1.31) 0.807 1.64 (1.28–2.10) <0.001
 LDL 
  Large 0.77 (0.60–0.98) 0.036 0.61 (0.46–0.81) <0.001
  Small 0.69 (0.52–0.93) 0.013 0.89 (0.67–1.18) 0.422
 VLDL and chylomicron
  Large 0.89 (0.68–1.16) 0.378 0.64 (0.44–0.93) 0.020
  Medium 0.71 (0.54–0.95) 0.020 0.30 (0.19–0.47) <0.001
  Small 0.88 (0.68–1.14) 0.335 1.01 (0.78–1.32) 0.913
Mean particle sizes
 HDL particle size 1.29 (0.98–1.70) 0.070 1.75 (1.28–2.40) <0.001
 LDL particle size 1.22 (0.94–1.60) 0.140 1.10 (0.82–1.49) 0.520
 VLDL particle size 1.06 (0.83–1.35) 0.652 1.10 (0.84–1.45) 0.477
a The OR relating a one SD increase in lipoprotein to early/late stage AMD was estimated from separate multiple logistic regression models 
adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering medication, self-reported hypertension, diabetes, myocardial 
infarction, and stroke.
bP-values were derived from Wald tests of the corresponding logistic regression coefficient relating each lipoprotein to early/late-stage AMD.
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lipids that is most affected by food intake and is, on aver-
age, 0.3 mmol/l higher in nonfasting samples than in fast-
ing samples (67). We did not see any significant differences 
in TG levels between cases and controls. Second, postpran-
dial changes in lipoprotein particles have been studied 
using NMR in more than 1,000 men and women (69). In 
this study, both men and women exhibited a reduction 
in the total LDL-particle concentration following a meal, 
which was associated with an increase in IDL and large 
LDL particles and a reduction in small LDL particles. In 
our study, we observed reduced total LDL particle concen-
tration, increased IDL particle concentration, and reduced 
small LDL particle concentration. However, unlike the 
observation following a meal, when large LDL particle 
concentration increased, we observed a reduction in 
large LDL particle concentrations, which was highly statis-
tically significant. This suggests that the differences ob-
served between cases and controls may not relate to food 
intake. To further evaluate the potential effects of differ-
ences in the way samples were collected among cases and 
TABLE 6. Lipoprotein profiles in controls and late AMD cases according to CETP D442G status
Mean (SD) P a P a
Controls Late AMD Controls Late AMD
Without D442G  
(n = 276)
With D442G  
(n = 121)
Without D442G  
(n = 164)
With D442G  
(n = 29)





569.2 (232.2) 432.9 (189.5) 538.1 (302.7) 528.9 (342.7) <0.001 0.773
Conventional lipid biochemistry
 HDL-C, mmol/l 1.3 (0.4) 1.5 (0.5) 1.4 (0.3) 1.5 (0.4) <0.001 0.497
 LDL-C, mmol/l 3.1 (0.9) 3.4 (0.9) 3.0 (1.0) 2.9 (1.0) 0.247 0.892
 TG, mmol/l 1.8 (1.1) 1.8 (1.2) 1.9 (1.0) 1.6 (0.7) 0.515 0.509
Total particle concentration by subclass
 ApoA1, mg/dl 155.1 (26.4) 160.3 (25.0) 144.2 (47.0) 151.4 (35.8) 0.529 0.968
 HDL, µmol/l 35.1 (6.0) 36.9 (6.2) 37.1 (7.4) 37.9 (7.2) 0.379 0.272
 LDL, nmol/l 1,326.5 (446.0) 1,316.4 (428.2) 1,264.9 (425.3) 1,076.4 (328.6) 0.387 0.487
 VLDL and chylomicron lipoprotein, nmol/l 73.3 (30.4) 71.6 (26.8) 61.3 (24.0) 56.4 (17.2) 0.674 0.303
Lipoprotein size distribution by subclass
 HDL 
  Large 7.0 (3.7) 7.9 (3.9) 6.7 (3.2) 8.2 (4.8) 0.092 0.308
  Medium 9.0 (5.0) 9.3 (4.7) 10.4 (5.1) 10.7 (4.4) 0.728 0.255
  Small 19.2 (6.3) 19.8 (5.7) 20.1 (6.6) 19.0 (4.8) 0.710 0.512
 IDL 
110.9 (80.2) 124.4 (92.2) 157.5 (112.0) 145.2 (103.5) 0.111 0.726
 LDL 
  Large 578.2 (268.4) 633.2 (269.7) 443.1 (260.5) 477.6 (320.0) 0.294 0.319
  Small 637.5 (430.5) 558.8 (431.3) 664.2 (386.2) 453.6 (243.8) 0.069 0.122
 VLDL and chylomicron
  Large 6.7 (6.4) 6.7 (5.5) 5.2 (3.9) 5.1 (3.3) 0.973 0.292
  Medium 31.0 (19.5) 23.5 (16.0) 18.1 (12.6) 14.4 (7.7) 0.003 0.191
  Small 35.6 (17.9) 41.4 (18.7) 38.0 (16.6) 36.9 (15.9) <0.001 0.773
 Mean particle size
  HDL particles, nm 9.2 (0.5) 9.3 (0.5) 9.3 (0.5) 9.4 (0.5) 0.088 0.115
  LDL particles, nm 20.9 (0.6) 21.1 (0.7) 20.8 (0.6) 21.0 (0.6) 0.003 0.346
  VLDL and chylomicron, nm 49.8 (7.6) 50.9 (7.8) 50.4 (7.5) 51.6 (8.1) 0.192 0.450
aP-values were derived from t-tests of the adjusted difference in mean lipoprotein level between mutation carriers and noncarriers (for cases and 
controls separately) in a multiple linear regression model adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering 
medication, self-reported hypertension, diabetes, myocardial infarction, and stroke.
TABLE 7. Interaction between HDL particle concentration and CETP D442G mutation on the risk of nAMD
Group without D442G 
mutation (n = 440)
Group with D442G  
mutation (n = 37) Interaction coefficientb 
Number with AMD 164 29 —
Percentage with AMD (%) 37.3 78.4 —
Effect of total HDL particle concentration on AMD
 ORa per SD increase in total 
HDL particle concentration
1.32 (1.06–1.65) P = 0.014 0.44 (0.16–1.20) P = 0.107 0.33 (0.12–0.93) P = 0.036
Effect of medium-sized HDL particle concentration on AMD:
 ORa per SD increase in 
medium-sized HDL particle 
concentration
1.30 (1.06–1.61) 0.014 0.34 (0.10–1.18) 0.088 0.26 (0.07–0.92) 0.037
a The OR relating increase in each lipoprotein to late-stage AMD by mutation carrier status was estimated from 
a logistic regression model that included an interaction term between the lipoprotein and mutation status, in 
addition to their primary effects, age, gender, BMI, smoking status, average axial length, lipid-lowering medication, 
self-reported hypertension, diabetes, myocardial infarction, and stroke.
b The interaction coefficient estimates the ratio of the OR in mutation carriers to that in noncarriers in the 
abovementioned model, with the P-value derived from a Wald test of the said coefficient.
 at W
ashington Univ M












Supplemental Material can be found at:
1794 Journal of Lipid Research Volume 58, 2017
controls, we also evaluated the lipoprotein particle concen-
trations in 17 subjects from the Singapore Chinese Eye 
Study who had nAMD and had blood available that had 
been collected at the same time and using the same proto-
col as the controls utilized in this study. The results from 
these 17 subjects are presented alongside our findings in 
supplemental Table S1. The low concentrations of medium 
VLDL and large LDL particles, accompanied by high con-
centrations of IDL particles that we observed in cases com-
pared with controls were also observed in these 17 cases 
derived from the Singapore Chinese Health Study (the 
study from which the controls were derived). In relation to 
HDL, there was a relatively larger proportion of large HDL 
particles in these cases compared with controls (as we saw 
with the other cases), reflected as a larger HDL particle 
size. However, the concentrations of the individual HDL 
species were dissimilar from the other cases. Chylomicron 
concentrations were also different in these 17 cases com-
pared with the cases derived from the Asian AMD pheno-
typing study. Thus, although we are reasonably confident 
in our findings related to VLDL, IDL, and LDL particles, 
we feel that some of these studies should be repeated in 
a study with fasting collection of samples, which may be 
particularly relevant to our understanding of the role of 
chylomicron and HDL particles in the pathogenesis of 
AMD.
CONCLUSION
To conclude, we demonstrate that altered concentra-
tion of lipoprotein particles are associated with AMD that 
are not captured by conventional lipid measures. We re-
port that nAMD is associated with higher concentrations 
of HDL particles, particularly medium-sized HDL parti-
cles, and IDL particles, and lower concentration of VLDL 
and chylomicron and Apo A-1. These relationships were 
not mediated by the CETP D442G mutation. However, the 
associations may be modulated by the presence of this mu-
tation. Although our study does not provide definitive 
proof of a causal link between dyslipidemia and AMD, it 
does support the relevance of the VLDLR KO mouse 
model of AMD to humans and raises the possibility that 
therapies that increase the supply of fatty acids through 
VLDL to the retina, or that may reduce the reliance on 
lipids as a fuel, could be relevant to the prevention and 
treatment of AMD.
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